Preparing Gen Z for a Lifetime of Leadership with Erica Molett

When introducing Erica Molett, it can be hard to know where to begin. She has founded and is currently the CEO of three different organizations: Kandake Tech, Beyond the Ball, and Expansion Solutions Consulting. While that might be a lot for some people, she isn’t stopping there. 

“There are innovations that are being birthed out of those (three)…we’re building platforms that will eventually fly away and live on their own,” Molett told host Adam Morrisey. 

Each of these organizations has the same goal of setting up Gen Z for success in the future. Erica believes that achieving this is a crucial goal because of the special role Gen Z can play in the future.

“There was a report that Bank of America had written about Gen Z, that said [they] will be the most disruptive and innovative generation ever,” she said. 

Molett believes that in order to help young people reach their full potential, it’s important to engage with them in their specific areas of interest, like sports, gaming, or technology. One of the most effective ways she has found to do this is by bringing in representatives from high-profile companies like Nike and Microsoft to speak to these students. 

“The journey of the guy in the marketing department at the Jordan Brand is just as important and more easily applicable to a kid’s life as Serena Williams. Jeff Harris from Jordan Brand, there are thousands of kids who could follow in his footsteps. There might be one kid that could follow in Serena’s footsteps on the court,” said Molett. 

For more on Erica Molett and the work she is doing, follow her on her LinkedIn page.

Follow us on social media for the latest updates in B2B!

Image

Latest

vitro
Analyzing the Suppressive TME in In Vitro Based Assays
April 19, 2025

In the rapidly advancing field of cancer immunotherapy, accurately modeling the tumor microenvironment (TME) has become essential to improving the predictive power of preclinical drug testing. As immune-modulating therapies surge forward, with over 4,000 immune modulators in development globally, scientists are refining assay technologies that maintain the complexity of patient-specific tumor biology. In vitro platforms…

Read More
cancer
Targeting T Cells Within the Cancer Immunity Cycle
April 19, 2025

As cancer immunotherapy continues to reshape treatment landscapes, fine-tuning T-cell responses has become a critical frontier. Recent advances in 3D organoid models and high-content imaging are enabling scientists to closely mimic patient-specific tumor environments—unlocking insights into how T cells behave, respond, and falter under immune checkpoint blockade. With over 4,000 immune modulators in clinical…

Read More
cancer Immunity cycle
Advanced In Vitro Technologies to Investigate Therapeutic Impact on the Cancer Immunity Cycle
April 19, 2025

As immunotherapy revolutionizes cancer treatment, the need for physiologically relevant preclinical models becomes more urgent than ever. Despite the success of immune checkpoint inhibitors, a large majority of patients fail to achieve long-lasting responses, prompting researchers to explore more complex and predictive assays. The cancer immunity cycle, first described in 2013, remains a central framework…

Read More
resistance
Inside Oncology Drug Development: Overcoming Resistance with Science
April 19, 2025

In the last two decades, oncology has undergone a transformation with over 300 new cancer therapies approved by the FDA—many offering novel mechanisms of action. Despite these innovations, resistance to treatment remains a critical challenge, with cancer cells evolving or adapting to evade even the most advanced therapeutics. This issue is particularly pressing given that…

Read More